GlassScriptPhysician profile
Minal Patel
NPI 1588848089
$5,980.95
in general payments reported to CMS, 2019-2025
29 companies · $535 in 2025
The $535 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $509 · 2021: $718 · 2022: $1,074 · 2023: $1,094 · 2024: $1,341 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,847.35 | 2019-2025 | Exalt Model D, X-Tack Endoscopic Helix Tacking System |
| Abbvie INC. | $1,361.35 | 2019-2025 | |
| Pfizer INC. | $450.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.89 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.51 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $206.32 | 2019-2021 | |
| Medtronic, INC. | $163.06 | 2022 | |
| Celgene Corporation | $162.76 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $132.51 | 2019-2022 | |
| Ethicon US, LLC | $121.57 | 2019-2025 | Linx Reflux Management System |
| Olympus America INC. | $119.97 | 2023 | Endoclot Phs |
| Genzyme Corporation | $119.82 | 2019-2024 | |
| Enterra Medical, INC. | $117.64 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $106.51 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $78.25 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $75.45 | 2023-2024 | Omvoh, Emgality, Reyvow |
| Gilead Sciences, INC. | $67.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $41.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $34.52 | 2025 | Vowst |
| Covidien LP | $33.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $28.88 | 2019 | |
| Amgen INC. | $25.66 | 2021 | |
| Daiichi Sankyo INC. | $20.69 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.51 | 2024 | |
| Endo Pharmaceuticals INC. | $17.07 | 2019 | |
| Echosens North America, INC. | $16.22 | 2019 | |
| Shire North American Group INC | $13.22 | 2019 | |
| Organon LLC | $12.45 | 2021 | |
| Braintree Laboratories, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.